Atomoxetine Dosage and Administration for ADHD

Initial Dosing and Titration

The American College of Obstetricians and Gynecologists recommends starting atomoxetine at 40 mg orally once daily, then titrating every 7-14 days to 60 mg and then 80 mg daily, with a maximum dose of 1.4 mg/kg/day or 100 mg/day, whichever is less 1, 2, 3
Begin with 40 mg orally once daily as the standard starting dose, with adjustments based on clinical response and tolerability 1, 2, 3
Adjust the dose every 7-14 days, progressing from 40 mg daily to 60 mg daily, then to 80 mg daily 1, 2, 3
The maximum dose is the lesser of 1.4 mg/kg/day or 100 mg/day 1, 2, 3

Maintain weekly contact during initial titration and dose adjustments, and systematically assess for specific side effects at each adjustment 4
Allow 6-12 weeks for full therapeutic effects to be observed, as atomoxetine has a slower onset compared to stimulants 5
After dose stabilization, schedule follow-up appointments at least monthly, and consider alternative treatments or adding non-stimulant medications if adequate symptom control is not achieved at maximum dose 4

Atomoxetine is generally used as second-line therapy after stimulants, though it may be first-line in specific circumstances, such as patients with comorbid substance use disorders or tic/Tourette's disorder 5
Consider atomoxetine as first-line in patients who prefer a non-controlled substance, due to its negligible abuse potential and lack of controlled substance status 5

For preschool-aged children (4-5 years), the American Academy of Pediatrics recommends starting with lower doses and increasing in smaller increments due to slower metabolism rates 6, 7
The American Academy of Pediatrics suggests considering atomoxetine as first-line therapy in patients with comorbid substance use disorders or risk of substance abuse, as it has negligible abuse potential 6, 7
In adolescents, the American Academy of Pediatrics recommends assessing for substance abuse symptoms before initiating treatment and monitoring prescription-refill requests for signs of misuse or diversion 6, 7
The American Academy of Pediatrics advises considering longer-acting coverage for symptom control while driving in adolescents 6, 7